

2019 Spring Meeting of Participants

PLENARY SESSION AND RECOGNITION AWARDS CEREMONY

Friday, May 3, 2019

4:30 – 6:00 pm

MOUNTBATTEN BALLROOM

Plenary Session Co-Chairs: Drs Annette Hay, Martin Smoragiewicz

4:30 – 4:35	WELCOME	
4:35 – 4:45	IND.228: A Phase II Study of Durvalumab and Tremelimumab in Patients with Advanced Rare Tumours	Abha Gupta
4:45 – 4:55	CO.26: A Phase II Randomized Study of Durvalumab and Tremelimumab and Best Supportive Care vs Best Supportive Care Alone in Patients with Advanced Colorectal Adenocarcinoma Refractory to Standard Therapies	Eric Chen
4:55 – 5:05	MAC.12 (ECOG PACCT-1): Trial Assigning Individualized Options for Treatment: The TAILORx Trial	Kathy Pritchard
5:05 – 5:15	MAC.7 (SWOG S0226): Phase III Randomized Trial of Anastrozole Versus Anastrozole and Fulvestrant as First-Line Therapy for Post-Menopausal Women With Metastatic Breast Cancer	Ted Vandenberg
5:15 – 5:25	CLC.2 (Alliance A041202): A Randomized Phase III Study of Bendamustine plus Rituximab versus Ibrutinib plus Rituximab versus Ibrutinib Alone in Untreated Older Patients (> = to 65 years of age) with Chronic Lymphocytic Leukemia	Matthew Cheung